Search

Displaying results 621 - 630 of 3917 in total
  1. Drug

    AZD0947

    go.drugbank.com/drugs/DB04848
    Experimental

    As of March 2003, the drug was in phase II trials; however, as of October 2004, it no longer appeared on the company’s development pipeline.

  2. Drug

    Saxagliptin

    go.drugbank.com/drugs/DB06335
    ApprovedInvestigational

    FDA approved on July 31, 2009.

  3. Drug

    Zanubrutinib

    go.drugbank.com/drugs/DB15035
    ApprovedInvestigational

    [L10163] Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long-term survival. … Zanubrutinib was granted accelerated approval by the FDA in November 2019 based on clinical trial results that demonstrated an 84% overall response rate from zanubrutinib therapy in patients with MCL,[

  4. Drug

    Carbazochrome

    go.drugbank.com/drugs/DB09012
    ApprovedWithdrawn

    In the future this may prevent excessive blood flow during surgical operations and the treatment of hemorrhoids, but research on effectiveness and severity of side effects remains inconclusive. … Carbazochrome has been investigated for use in the treatment of non-surgical acute uncomplicated hemorrhoids in a mixture with [DB13124], and this combination therapy demonstrated efficacy and safe tolerability

    International brands: Su Bo Te
  5. Drug

    Nadolol

    go.drugbank.com/drugs/DB01203
    ApprovedInvestigational

    [A34177] Nadolol was granted FDA approval on 10 December 1979.[L7922]

    Categories: Beta Blocking Agents, Non-Selective, Beta Blocking Agents, Non-Selective, and Thiazides
  6. Drug

    Dexbrompheniramine

    go.drugbank.com/drugs/DB00405
    Approved

    Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria.

    Mixtures: G-Con-X
  7. Drug

    Sotalol

    go.drugbank.com/drugs/DB00489
    ApprovedInvestigational

    [A178579] Sotalol was first approved as an oral tablet on 30 October 1992.

    Categories: Beta Blocking Agents, Non-Selective, Beta Blocking Agents, Non-Selective, and Thiazides
  8. Drug

    Helium

    go.drugbank.com/drugs/DB09155
    ApprovedInvestigationalVet approved

    It is a colorless, odorless, tasteless, non-toxic, inert, monatomic gas located at the top of the noble gases on the periodic table.

  9. Drug

    Camizestrant

    go.drugbank.com/drugs/DB19218
    ApprovedInvestigational

    [L64094,L64107] The European Commission approved camizestrant on July 23, 2026, Health Canada authorized it on August 4, 2026, and the FDA granted accelerated approval on September 4, 2026. … [L64094,L64107] Patients are selected for treatment on the basis of an *ESR1* mutation detected by circulating tumor DNA testing during first-line endocrine therapy, before radiographic disease progression

  10. Drug

    Flumazenil

    go.drugbank.com/drugs/DB01205
    ApprovedInvestigational

    receptor complex, thereby reversing the effects of benzodiazepine on the central nervous system. … Fumazenil is an imidazobenzodiazepine derivative and a potent benzodiazepine receptor antagonist that competitively inhibits the activity at the benzodiazepine recognition site on the GABA/benzodiazepine